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Abstract We performed case–control analyses using data
from the North Carolina Ovarian Cancer Study to deter-
mine risk factors that distinguish primary peritoneal cancer
(PPC) from epithelial ovarian cancer (EOC). Our risk
factor analyses were restricted to invasive serous cancers
including 495 EOC cases, 62 PPC cases and 1,086 control
women. Logistic regression analyses were used to calculate
adjusted odds ratios and 95% conﬁdence intervals for risk
factor associations. Although many case–control associa-
tions for the invasive serous PPC cases were similar to
those of the invasive serous EOC cases, some differences
were observed including a twofold increase in risk of
invasive serous PPC in women who were C35 years at last
pregnancy, whereas a decreased risk was observed for
invasive serous EOC risk. We could not conﬁrm a previous
report of an association between tubal ligation and PPC, a
factor consistently associated with a decreased risk of
EOC. The difference in the risk factor associations between
invasive serous PPC and EOC cancers suggests divergent
molecular development of peritoneal and ovarian cancers.
A larger study to determine risk factors for invasive serous
PPC is warranted.
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Introduction
Primary peritoneal cancer (PPC) arises in the tissue that
lines the abdominal cavity and pelvic cavity [1]. It is an
uncommon disease that shares many histopathologic and
clinical characteristics with epithelial ovarian cancer
(EOC), but PPC is distinguished by the absence of a
malignant/invasive ovarian mass [2]. The incidence of PPC
is considerably lower than that of EOC (6.78 cases per
million vs. 120.5 cases per million, respectively), but PPC
incidence has increased at a faster rate than ovarian cancer
over the past three decades [3, 4]. However, it is not clear
whether this change is due to diagnostic changes or a true
increase.
It is uncertain whether PPC is a distinct disease from
EOC or if they share common origins. Features shared by
both PPC and EOC include the preponderance of serous
histology, the advanced stage at diagnosis for the majority
of women and similar responsiveness to platinum/taxane
chemotherapy [2]. The similarities of these cancers as well
as cancers of the fallopian tubes have led to the suggestion
that each of these cancer types develops from a common
cell lineage, the embryonic Mt ‹ llerian system [5]. Evidence
supporting this argument is the observation that destruction
of portions of the Mt ‹ llerian duct by tubal ligation or hys-
terectomy reduces the risk of ovarian cancer [5].
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limited [6–8]. A recent study from Australia [8] reported
many similarities in risk factors for PPC and EOC, but also
reported that parous women are at increased risk of PPC.
This same study found that obesity was associated with risk
of PPC but not EOC. It has been reported that BRCA1 and
BRCA2 mutation carriers, including those who have
undergone prophylactic bilateral oophorectomy, are at
increased risk of PPC [9, 10]. The observed differences in
relationships with certain risk factors are suggestive that
PPC and EOC may be distinct disease entities, but further
data from other studies are needed. In this paper, we
present results of an analysis that compared clinical char-
acteristics and risk factors for EOC and PPC of invasive
serous histology in a population-based, case–control study
in North Carolina.
Materials and methods
Study population
The subjects in this study are from the North Carolina
Ovarian Cancer Study (NCOCS), a population-based,
case–control study of EOC conducted in a 48-county
region of North Carolina between 1999 and 2007. Women
diagnosed with PPC were also enrolled. Identiﬁcation and
recruitment of EOC and controls has been described in
detail in other reports [11–13]. Identical recruitment pro-
cedures for EOC cases were applied to PPC cases. Brieﬂy,
newly diagnosed cases of primary peritoneal and epithelial
ovarian cancer were identiﬁed through the North Carolina
Central Cancer Registry using a rapid case ascertainment
system. Pathology reports for eligible cases were sent to the
study ofﬁce at Duke University Medical Center, and con-
sent to contact the women was requested from the treat-
ing physicians. Eligible EOC and PPC cases were aged
20–74 years at diagnosis, had no prior history of ovarian
cancer, resided in the study area and were cognitively able
to give consent and complete an interview in English. All
cases underwent centralized histopathologic review by the
study pathologist (RCB) to conﬁrm the diagnosis. Cases
were classiﬁed by the study pathologist as PPC if they met
the Gynecologic Oncology Group criteria [14]: (1) ovaries
are normal in size or enlarged by a benign process; (2) the
extraovarian sites of carcinoma are of signiﬁcantly greater
volume than the tumor present on either ovary; (3) the
ovarian tumor component is nonexistent, conﬁned to the
ovarian surface with or without stromal invasion measuring
in aggregate less than 5 9 5 mm, or within the ovarian
substance and measuring less than 5 9 5 mm; and (4) the
histologic characteristics indicate serous carcinoma of any
grade.
Control women were frequency-matched by age (5 year
age categories) and race (Black or other) to both invasive
and low malignant potential EOC cases who resided in the
same 48-county region as the EOC cases using list-assisted
random digit dialing. In the present analysis, the age dis-
tribution of the cases is somewhat older than that of the
controls because we excluded the low malignant potential
cases that have a younger age at diagnosis than the invasive
cases. Eligibility for controls included at least one intact
ovary.
The response rate among the epithelial EOC cases was
66.2%, with nonparticipation due to subject refusal
(11.6%), death (4.1%), debilitating illness (2.6%), physi-
cian refusal (4.7%) and inability to locate (10.8%). The
response rate for PPC cases was 72.8%, with nonpartici-
pation due to subject refusal (7.0%), death (8.8%), debili-
tating disease (3.5%), physician refusal (1.8%) and
inability to locate (6.1%). Seventy-three percent of poten-
tial controls who passed the eligibility screening agreed to
be sent information about the study, and 62% of those
consented to be in the study. Nonparticipation was due to
subject refusal (28%) and inability to contact (10%).
The study protocol was approved by the Duke Univer-
sity Medical Center Institutional Review Board and the
human subjects committees at the North Carolina Central
Cancer Registry and each hospital where cases were
identiﬁed.
In-person interview
For all study subjects, nurse-interviewers conducted
in-person visits where they obtained written informed
consent, administered a 90-minute standardized question-
naire, drew a blood sample and performed anthropometric
measurements (height, weight and waist and hip circum-
ferences). Information obtained with the questionnaire
included established and suspected ovarian cancer risk
factors including family history of cancer, menstrual
characteristics, reproductive history, hormone and contra-
ceptive use, and lifestyle characteristics such as smoking,
alcohol consumption and physical activity. A life-events
calendar, which marked milestones such as marriages and
births, was used to aid recall of reproductive history and
hormone use. Pictures of oral contraceptives (OCs), men-
opausal hormones and certain other medications were also
used to assist with recall.
Statistical analysis
Chi-square analyses were used to compare clinical and
histologic characteristics between PPC and EOC cases.
Unconditional logistic regression analyses were used to
calculate age- and race-adjusted and multivariable-adjusted
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separately for each disease (PPC or EOC) versus controls.
To assess the possibility of residual confounding due to
age, we determined whether the addition of the quadratic or
cubic terms for age at diagnosis/interview improved the ﬁt
of the model. For most variables, the linear term for age
produced the best ﬁt. There was no evidence that the cubic
age terms improved the ﬁt for any of the analyses in
Table 2. Inclusion of both the linear and quadratic terms
for age improved the ﬁt of the model for age at last
pregnancy, and therefore, the results for this analysis were
age-adjusted by including both terms in the model. Case–
control analyses for both PPC cases and EOC cases were
restricted to invasive cancers of the serous histologic sub-
type since this was the largest category for all cancers.
Variables examined included number of pregnancies (0,
1–2, 3–4, 5?); ever been pregnant (yes or no); age at last
pregnancy (ages 14–24, 25–29, 30–34, 35?); ever breast
fed (yes or no), age at menarche (age 0–\12, 12?); men-
opausal status (postmenopausal or premenopausal); tubal
ligation (yes or no); hysterectomy at least 1 year prior to
diagnosis/interview (yes or no); history of doctor-diag-
nosed infertility (yes or no); years of OCs or patch use (\1,
1–\5, 5?); menopausal hormones (yes or no); family
history of ovarian cancer in a ﬁrst degree relative (yes or
no); family history of breast cancer in a ﬁrst degree relative
(yes or no); talc use (yes or no); and body mass index
(BMI) 1 year before diagnosis (measurements 13–\25, 25–
\30, 30–\35, 35? kg/m
2). To test statistical signiﬁcance
of differences in age-at-last-pregnancy trends between PPC
and EOC cases, we used logistic regression controlling for
age, race and number of pregnancies and restricting sub-
jects to those who were ever pregnant. To test for possible
heterogeneity for risk factor associations in PPC and EOC,
we performed case-only comparisons for age at last preg-
nancy, a family history of breast cancer and hysterectomy
using logistic regression, adjusting for both age and race.
Results
Clinical characteristics of the PPC and EOC cases enrolled
in NCOCS are found in Table 1. While a majority of both
the PPC and EOC cases were invasive, a larger proportion
of low malignant potential tumors were found in the EOC
cases (20.5% vs. 5.1% of the PPC cases). We found sta-
tistically signiﬁcant differences in the distributions of his-
tologic subtypes of women with invasive PPC compared to
those diagnosed with invasive EOC; a larger portion of the
invasive PPC cases were serous compared to the invasive
EOC cases. Among the invasive serous cases, women with
PPC were less likely to have a well-differentiated grade
compared to invasive EOC cases. Invasive serous PPC
cases were also more likely to be diagnosed at later stages
than the invasive serous EOC cases, 95.2% versus 85.3%,
respectively.
The case–control analyses to determine risk factor
associations were restricted to 62 PPC and 495 EOC cases
of invasive serous histology and are summarized in
Table 2. When compared to EOC cases, the PPC cases
Table 1 Tumor characteristics of primary peritoneal cancer and epithelial ovarian cancer cases
Primary peritoneal cancer Ovarian cancer p-value
All cases (n = 78) (n = 1107)
Tumor behavior Low malignant potential 4 (5.1%) 227 (20.5%) 0.001
Invasive 72 (92.3%) 877 (79.2%)
Missing 2 3
Invasive cases (n = 72) (n = 877)
Histology Serous 62 (86.1%) 495 (56.4%) \0.0001
Clear cell 3 (4.2%) 87 (9.9%)
Endometrioid 139 (15.8%)
Mucinous 48 (5.5%)
Other 7 7(9.7%) 108 (12.3%)
Invasive serous cases (n = 62) (n = 495)
Stage I or II 2 (3.2%) 70 (14.1%) 0.017
III or IV 59 (95.2%) 422 (85.3%)
Missing 1 3
Grade Well-differentiated 1 (1.6%) 45 (9.1%) 0.027
Moderately differentiated 30 (48.4%) 168 (33.9%)
Poorly or undifferentiated 30 (48.4%) 267 (53.9%)
Missing 1 15
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123Table 2 Age- and race-adjusted odds ratios (OR) and 95% conﬁdence intervals (CI) for case–control analyses of associations between
epidemiologic risk factors for invasive serous primary peritoneal cancer versus invasive serous epithelial ovarian cancer
Serous primary
peritoneal
cancer (N = 62)
Serous epithelial
ovarian cancer
(N = 495)
Controls
(N = 1086)
Serous primary
peritoneal cancer
versus controls
Serous epithelial
ovarian cancer
versus controls
N (%) N (%) N (%) OR (95% CI) OR (95% CI)
Age at diagnosis/age at interview (years)
20–49 4 (6.5) 98 (19.8) 325 (29.9)
50–59 21 (33.9) 164 (33.1) 339 (31.2)
60–69 24 (38.7) 162 (32.7) 288 (26.5)
70? 13 (21.0) 71 (14.3) 134 (12.3)
Missing . . .
Race
Black 4 (6.5) 67 (13.5) 189 (17.4)
White 56 (90.3) 419 (84.6) 868 (79.9)
Other 2 (3.2) 7 (1.4) 29 (2.7)
Missing . 2 .
Ever been pregnant
No 9 (14.5) 65 (13.1) 100 (9.2) 1.00 (Referent) 1.00 (Referent)
Yes 53 (85.5) 428 (86.5) 986 (90.8) 0.49 (0.23, 1.05) 0.59 (0.42, 0.83)
Missing . 2 .
Number of pregnancies
0 9 (14.5) 65 (13.1) 100 (9.2) 1.00 (Referent) 1.00 (Referent)
1–2 19 (30.6) 193 (39.0) 427 (39.3) 0.44 (0.19, 1.02) 0.63 (0.44, 0.91)
3–4 25 (40.3) 183 (37.0) 417 (38.4) 0.55 (0.24, 1.23) 0.59 (0.41, 0.85)
5? 9 (14.5) 52 (10.5) 142 (13.1) 0.48 (0.18, 1.30) 0.45 (0.28, 0.72)
Missing . 2 .
Ptrend 0.658 0.022
Age at last pregnancy years*
\25 6 (11.3) 117 (27.3) 215 (21.8) 1.00 (Referent) 1.00 (Referent)
25–29 17 (32.1) 155 (36.2) 318 (32.3) 1.65 (0.63, 4.29) 0.84 (0.62, 1.13)
30–34 18 (34.0) 100 (23.4) 290 (29.4) 2.20 (0.84, 5.72) 0.62 (0.45, 0.86)
35? 12 (22.6) 52 (12.1) 160 (16.2) 2.78 (1.00, 7.78) 0.58 (0.39, 0.86)
Missing . 4 3
Ptrend 0.126 0.001
Ever breastfed
No 45 (72.6) 344 (69.5) 695 (64.0) 1.00 (Referent) 1.00 (Referent)
Yes 17 (27.4) 151 (30.5) 391 (36.0) 0.71 (0.40, 1.27) 0.80 (0.64, 1.01)
Missing . . .
History of infertility
No 53 (85.5) 441 (89.1) 985 (90.7) 1.00 (Referent) 1.00 (Referent)
Yes 9 (14.5) 54 (10.9) 101 (9.3) 1.88 (0.89, 3.99) 1.26 (0.88, 1.79)
Missing . . .
Age at menarche years
0–\12 12 (19.4) 120 (24.2) 216 (19.9) 1.00 (Referent) 1.00 (Referent)
[=12 50 (80.6) 370 (74.7) 867 (79.8) 0.90 (0.46, 1.73) 0.72 (0.55, 0.93)
Missing . 5 3
Menopausal status
Postmenopausal 55 (88.7) 365 (73.7) 702 (64.6) 1.00 (Referent) 1.00 (Referent)
Premenopausal 7 (11.3) 122 (24.6) 378 (34.8) 0.53 (0.18, 1.54) 0.86 (0.60, 1.24)
Missing . 8 6
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123were older and a somewhat lower proportion was Black.
There was a signiﬁcantly increased risk associated with
hysterectomy status for both PPC and EOC, (OR = 1.98;
95% CI = 1.16, 3.37 and OR = 1.29; 95% CI = 1.01,
1.65, respectively). We also observed a signiﬁcant increase
in the risk of both diseases associated with individuals who
Table 2 continued
Serous primary
peritoneal
cancer (N = 62)
Serous epithelial
ovarian cancer
(N = 495)
Controls
(N = 1086)
Serous primary
peritoneal cancer
versus controls
Serous epithelial
ovarian cancer
versus controls
N (%) N (%) N (%) OR (95% CI) OR (95% CI)
Tubal ligation
No 41 (66.1) 353 (71.3) 686 (63.2) 1.00 (Referent) 1.00 (Referent)
Yes 21 (33.9) 140 (28.3) 399 (36.7) 1.10 (0.63, 1.93) 0.72 (0.57, 0.91)
Missing . 2 1
Hysterectomy 1 year prior to diagnosis/interview
No 36 (58.1) 345 (69.7) 834 (76.8) 1.00 (Referent) 1.00 (Referent)
Yes 26 (41.9) 148 (29.9) 251 (23.1) 1.98 (1.16, 3.37) 1.29 (1.01, 1.65)
Missing . 2 1
OC/patch use years
Never 26 (41.9) 169 (34.1) 308 (28.4) 1.00 (Referent) 1.00 (Referent)
0–\1 5 (8.1) 63 (12.7) 108 (10.0) 0.63 (0.24, 1.71) 1.14 (0.79, 1.65)
1–\5 12 (19.4) 114 (23.0) 291 (26.8) 0.80 (0.38, 1.70) 0.82 (0.61, 1.11)
5? 18 (29.0) 120 (24.2) 343 (31.3) 1.13 (0.56, 2.26) 0.74 (0.55, 1.00)
Missing 1 29 35
Ptrend 0.685 0.068
Menopausal hormones**
No 18 (32.7) 116 (31.8) 285 (40.6) 1.00 (Referent) 1.00 (Referent)
Yes 37 (67.3) 247 (67.7) 416 (59.3) 1.34 (0.74, 2.42) 1.42 (1.08, 1.86)
Missing . 2 1
1st Degree family history of ovarian cancer
No 56 (90.3) 463 (93.5) 1053 (97.0) 1.00 (Referent) 1.00 (Referent)
Yes 6 (9.7) 32 (6.5) 30 (2.8) 3.48 (1.36, 8.91) 2.42 (1.45, 4.05)
Missing . . 3
1st Degree family history of breast cancer
No 53 (85.5) 394 (79.6) 933 (85.9) 1.00 (Referent) 1.00 (Referent)
Yes 9 (14.5) 101 (20.4) 150 (13.8) 0.84 (0.40, 1.75) 1.52 (1.14, 2.01)
Missing . . 3
Talc use
No 31 (50.0) 204 (41.2) 412 (37.9) 1.00 (Referent) 1.00 (Referent)
Yes 17 (27.4) 158 (31.9) 275 (25.3) 0.76 (0.41, 1.42) 1.15 (0.89, 1.49)
Missing 14 133 399
BMI (kg/m
2) 1 year before diagnosis or interview
13–\25 29 (46.8) 193 (39.0) 409 (37.7) 1.00 (Referent) 1.00 (Referent)
25–\30 15 (24.2) 140 (28.3) 321 (29.6) 0.63 (0.33, 1.21) 0.92 (0.70, 1.19)
30–\35 8 (12.9) 81 (16.4) 172 (15.8) 0.69 (0.31, 1.56) 1.02 (0.74, 1.40)
35? 9 (14.5) 64 (12.9) 147 (13.5) 1.04 (0.47, 2.30) 1.01 (0.71, 1.43)
Missing 1 17 37
Ptrend 0.837 0.624
Adjustment for age at diagnosis/interview was accomplished in all the analyses using a linear term for age with the exception of age at last
pregnancy where both the linear term and quadratic terms were included
* Restricted to those ever pregnant and also controlling for number of pregnancies
** Among postmenopausal
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123have a ﬁrst degree family history of ovarian cancer. The
OR was 2.42 (95% CI = 1.45, 4.05) for invasive serous
EOC; the OR was even higher in magnitude for invasive
serous PPC with an OR of 3.48 (95% CI = 1.36, 8.91).
Among postmenopausal women, menopausal hormone use
was found to be signiﬁcantly associated with EOC with an
OR of 1.42 (95% CI = 1.08, 1.86). The association
between menopausal hormone use and PPC risk was not
signiﬁcant, but the OR was similar in magnitude to that of
EOC (OR = 1.34; 95% CI = 0.74, 2.42). Additionally, the
associations between a history of infertility and PPC and
EOC suggested an increased risk of both cancers with ORs
of 1.88 (95% CI = 0.89, 3.99) and 1.26 (95% CI = 0.88,
1.79), respectively, although neither was statistically
signiﬁcant.
Several epidemiologic risk factors were found to be
similarly inversely related to both invasive serous PPC and
invasive serous EOC. The ORs for PPC and EOC in those
women who reported that they had ever been pregnant
were 0.49 (95% CI = 0.23, 1.05) and 0.59 (95%
CI = 0.42, 0.83), respectively, and were similar in mag-
nitude. Additionally, the ORs for having ever breast fed,
age at menarche, and menopausal status were also similar
in magnitude and direction of the association for both
cancer types, although most of the associations were not
statistically signiﬁcant.
Some differences in the association with the risk of the
two cancers types were noted. Speciﬁcally, among women
who were ever pregnant, although of borderline statistical
signiﬁcance, we observed over a twofold increased risk of
invasive serous PPC in women who were C35 years at
last pregnancy (OR = 2.78; 95% CI = 1.00, 7.78, Ptrend =
0.126). In contrast, a decreasing risk with increasing age at
last pregnancy was observed for women diagnosed with
invasive serous EOC (OR = 0.58; 95% CI = 0.39, 0.86;
Ptrend = 0.001). Using logistic regression comparing inva-
sive serous PPC cases to invasive serous EOC cases, we
found a greater than fourfold difference in the association
with an age at last pregnancy C35 years (OR = 4.61; 95%
CI = 1.61, 13.10; Ptrend = 0.009) among those who were
ever pregnant (data not shown). Analysis of the association
with age at ﬁrst pregnancy and invasive serous PPC and
EOC was also consistent with the associations with age at
last pregnancy, where no association with PPC was
detected, and increasing age at ﬁrst birth was associated
with a decreased risk of EOC. (data not shown) Although a
signiﬁcant trend for decreasing risk of EOC with increasing
number of pregnancies was observed, a similar trend was
not observed for PPC risk. For women with invasive serous
PPC, no association with having had a tubal ligation
(OR = 1.10; 95% CI = 0.63, 1.93) was observed, while
having a tubal ligation was inversely related to invasive
serous EOC risk (OR = 0.72; 95% CI = 0.57, 0.91).
However, in a case-only analysis comparing the PPC cases
to the EOC cases, the difference in the association with
tubal ligation was not statistically signiﬁcant (p = 0.165).
Having a family history of breast cancer was not found to
be associated with invasive serous PPC in our data
(OR = 0.84; 95% CI = 0.40, 1.75), while an increased
risk of invasive serous EOC was observed (OR = 1.52;
95% CI = 1.14, 2.01). However, a case-only comparison
of the association with a family history of breast cancer for
invasive serous EOC and PPC did not show evidence of
signiﬁcant heterogeneity in these estimates (p = 0.259).
Increasing years of use of OCs or the patch was found to be
associated with a decreasing trend for the risk of invasive
serous EOC. However, a similar trend was not observed for
invasive serous PPC most likely due to the small sample
size.
Neither cancer type was found to be associated with talc
use or a BMI[35 (see Table 2). However, to address the
possibility of confounding between duration of oral con-
traceptive/patch use, the number of pregnancies and BMI,
we simultaneously included all of these factors in an age-
and race-adjusted logistic regression model. We did not
observe substantial differences in the point estimates, as
shown in Table 2, for any of these three factors. (data not
shown)
Discussion
Our results of the case–control analyses suggest that there
were differences in some risk factors for invasive serous
PPC and EOC cases including a woman’s age at last
pregnancy, tubal ligation and family history of breast
cancer. Among women who were ever pregnant, those
whose age at last pregnancy was greater than 35 years had
increased risk of invasive serous PPC while this risk factor
was found to be protective against invasive serous EOC.
Additionally, no association between the risk of invasive
serous PPC and a family history of breast cancer and tubal
ligation was detected, while women with a family history
of breast cancer were at an increased risk of invasive serous
EOC and women who had a tubal ligation were at
decreased risk of invasive serous EOC.
The number of pregnancies was associated with a
decreased risk in both PPC and EOC in the current study.
Our results were not consistent with an Australian case–
control study published by Jordan et al. [8], where serous
cancers of the peritoneum were found associated with
increased risks among parous women (OR = 1.8, 95%
CI = 0.–3.9). An analysis by Eltabbakh et al. [6] showed
no difference between primary peritoneal and epithelial
ovarian cancer cases in women with high numbers of
children, although case–control associations were not
996 Cancer Causes Control (2010) 21:991–998
123measured. In the current study, we observed the novel
ﬁnding of a linear relationship between risk of invasive
serous PPC and age at last pregnancy, with over a twofold
increase in risk at C35 years at last pregnancy, while this
risk factor was protective in invasive serous EOC cases in
the current study. The association between a woman’s age
at last pregnancy and increased risk of invasive serous PPC
in the current study is also inconsistent with the inverse
relationship with ovarian cancer in previous studies [15].
Our results showing an increasing risk of invasive serous
PPC with older age at last pregnancy suggest differences in
cancer development between peritoneal and ovarian car-
cinomas. The development of peritoneal cancer may not be
linked to the protective apoptotic effect resulting in the
clearing of mutated cells due to elevated progesterone
during pregnancy as hypothesized for ovarian cancer [16].
The contrasting results for risk of PPC and EOC are sug-
gestive of etiological differences in these diseases or tissue
origins. If conﬁrmed, this novel ﬁnding will need further
study to more fully understand the biological basis for why
age at last pregnancy would differentially affect the risk of
PPC and EOC.
The associations between several other ovarian cancer
risk factors and invasive serous PPC are not consistent with
that of previous reports. For example, our results of no
association of risk with family history of breast cancer
were also not consistent with the Australian study that
found a family history of breast cancer was associated with
an increased risk of PPC [8]. The lack of association with
risk of PPC in women with tubal ligation in the current
study is also in contrast to the protective effect observed for
PPC in a larger, previous case–control study in the Aus-
tralia [8]. In the current study, we did not observe signiﬁ-
cant association between age at menarche and invasive
serous PPC, although the OR was less than 1.0 for age at
menarche [12 years of age. These results were not con-
sistent with the study by Eltabbakh et al. [6], which showed
that women with serous PPCs had later age at menarche
when compared to those with EOC (13.3 years vs.
12.8 years; p = 0.02). However, a small study by Halperin
et al. [7] reported that women with serous PPC (N = 28)
had a signiﬁcantly earlier age at menarche compared to
controls. Small sample sizes likely contributed to these
inconsistent ﬁndings. Our ﬁndings are also inconsistent
with that of the Australian study that reported obese
women with a BMI [30 had double the risk of PPC
(OR = 2.1; 95% CI = 1.3–3.4).
In addition, our results showed that women who had a
hysterectomy had an increased risk of both PPC and EOC.
The study in Australia by Jordan et al. [8] also showed an
increased risk of both cancers. Both studies are inconsistent
with conclusions established in previous studies [17]. The
results in the Australian study were attributed to a lower
age-standardized rate of hysterectomies in the study con-
trols compared to respondents in the 2001 Australian
National Health Survey [8]. The prevalence of hysterec-
tomy of 23.1% in the controls of the NCOCS is similar to
that in the general population of North Carolina of 24.6%
as shown in the 2008 North Carolina Behavioral Risk
Factor Surveillance Study statistics [18].
Although the prevalence of hysterectomy in our control
group is a little lower than in the North Carolina popula-
tion, this difference would not explain the entire increase in
cases that was observed. Therefore, the association with
hysterectomy and both EOC and PPC cases in the NCOCS
may need further study to determine whether bias or
chance explains our unexpected ﬁndings.
Consistent with our results, the previous study by Jordan
et al. [8] also showed that perineal talc use had no effect on
the risk of peritoneal cancer. A second study of PPC,
however, reported fewer women with PPC used perineal
talc than women with ovarian cancer, 26.0 and 48.1%,
respectively (p = 0.003) [6]. Although chance due to small
sample sizes and misclassiﬁcation bias may play a role in
the inconsistent results, this study differed from the current
study as well as the Australian study by not restricting the
ovarian cancer cases to those of the serous histologic
subtype.
Strengths of this study are that it is population-based
and only incident cases of PPC and EOC were included.
Due to the large size of the NCOCS, we were able to
restrict the EOC cases to invasive serous cancers, thus
achieving a more homogenous group of ovarian cancers
with the same histology of the PPC cases. The small
sample size for PPC may have also contributed to our
inability to detect signiﬁcant associations in some
instances as well as some chance ﬁndings. Nonetheless,
the results of the current study provide evidence that
suggests etiologic differences between invasive serous
PPC and invasive serous EOC, underscoring the need for
further research in this area. Uncovering such differences
will improve the ability to intervene in the risk of
developing invasive serous PPC.
In conclusion, we found similar risk of invasive serous
PPC and invasive serous EOC for some but not all ovarian
cancer risk factors. Notably, we observed differences when
examining risk factors associated with age at last birth,
tubal ligation and family history of breast cancer. Studies
with larger sample sizes and population diversity are nee-
ded to establish risk factors associated with pathophysiol-
ogy of serous carcinomas.
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